GEORGE CHOLANKERIL to Fatty Liver
This is a "connection" page, showing publications GEORGE CHOLANKERIL has written about Fatty Liver.
Connection Strength
1.532
-
Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea". J Hepatol. 2024 May; 80(5):e218-e219.
Score: 0.786
-
Steatotic liver disease-associated all-cause/cause-specific mortality in the United States. Aliment Pharmacol Ther. 2024 07; 60(1):33-42.
Score: 0.199
-
The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults. J Pediatr Gastroenterol Nutr. 2024 Jul; 79(1):110-118.
Score: 0.199
-
Association between food insecurity and metabolic dysfunction-associated steatotic liver disease/significant fibrosis measured by fibroscan. Eur J Nutr. 2024 Apr; 63(3):995-1001.
Score: 0.196
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
Score: 0.052
-
Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality. J Gastroenterol Hepatol. 2024 Sep; 39(9):1950-1956.
Score: 0.050
-
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin Mol Hepatol. 2024 Jul; 30(3):436-448.
Score: 0.050